




Faculty of Health Sciences, UiT The Arctic University of Norway, June 2017 
Dioxin-like activity in blood from women with 
breast cancer and their age-matched controls 
Lise Custers Nedrebø 
Supervisors: Charlotta Rylander, Torkjel Sandanger 





I have been interested in what kind of effects all chemicals humans are producing and 
releasing into the environment may have on the environment, wildlife and humans. 
Therefore, I asked Torkjel Sandanger, which I had seen on the news on TV talking 
about environmentally damaging chemicals in baking paper and food wrapping on 
behalf of the Department of community medicine, University of Tromsø, if he had a 
project I could join. He assigned me this project to write under the supervision of 
Charlotta Rylander. The data in the study comes from the nationwide survey The 
Norwegian Women and Cancer (NOWAC) conducted by the Department of Community 
Medicine at the University of Tromsø and has long been waiting to be examined if 
there are any associations between dioxin-like activity in blood serum and risk of 
breast cancer. 
I must give a great thank you to Charlotta, who has helped me enormously with 
learning all the basics necessary to perform the statistical analyzes and guided me in 
how to write the thesis and keeping a time schedule. Also thank you to Torkjel, who 
was very helpful in getting me involved in the project and has given great advice and 
guidance as well. 
 
 
Lise Custers Nedrebø 











Preface ........................................................................................................................................ 1 
Contents ..................................................................................................................................... 3 
Summary .................................................................................................................................... 5 
1. Introduction/background ................................................................................................... 6 
1.1 Breast cancer ............................................................................................................... 6 
1.2 Dioxins and DLCs .......................................................................................................... 7 
1.2.1 Dioxins – a specific group of persistent organic pollutants(POPs) ...................... 7 
1.2.2 DLCs ...................................................................................................................... 8 
1.2.3 Physiochemical properties ................................................................................... 8 
1.2.4 Sources of dioxins and DLCs ................................................................................. 8 
1.2.5 Transfer of dioxins and DLCs in nature ................................................................ 9 
1.2.6 Human exposure routes to dioxins and DLCs .................................................... 10 
1.2.7 Trends of levels of dioxins and DLCs in humans ................................................ 11 
1.3 Endocrine disruption and health effects of dioxins/DLCs ......................................... 13 
1.3.1 Endocrine disruption .......................................................................................... 15 
1.3.2 Estrogen and estrogen receptor ........................................................................ 17 
1.3.3 The Aryl Hydrocarbon receptor ......................................................................... 18 
1.4 Epidemiologic studies on associations between dioxins, DLCs and cancer .............. 20 
1.5 Quantifying exposure to dioxins and DLCs ................................................................ 23 
1.5.1 Assessing dioxins and DLCs in humans............................................................... 23 
1.5.2 GC-MS and CALUX bioassay ............................................................................... 23 
1.5.3 Evaluating the toxicity of dioxins and DLCs - TEF/TEQ ....................................... 25 
1.6 Epidemiologic study designs ...................................................................................... 26 
1.7 Statistics ..................................................................................................................... 28 
1.7.1 Logistic regression .............................................................................................. 28 
4 
 
1.8 Aim ............................................................................................................................. 29 
2. Material and methods ...................................................................................................... 29 
2.1 The study group ......................................................................................................... 29 
2.1.1 Our study sample ............................................................................................... 30 
2.2 Analysis of serum ....................................................................................................... 31 
2.3 Exposure variables and covariates ............................................................................ 32 
2.3.1 Statistical analysis ............................................................................................... 34 
3. Results ............................................................................................................................... 34 
3.1 Study population characteristics ............................................................................... 34 
4. Discussion .......................................................................................................................... 38 
4.1 Strengths .................................................................................................................... 40 
4.2 Limitations ................................................................................................................. 41 
5. Conclusion ......................................................................................................................... 42 
6. References ........................................................................................................................ 43 
Appendix 1 ................................................................................................................................ 50 
Supervisor contract .................................................................................................................. 52 








Breast cancer is the most common cancer in women today, and although many risk 
factors are known, these cannot fully explain the vast increase in breast cancer 
incidences the last decades. Persistent organic pollutants have been indicated as 
potential carcinogenic compounds and it is therefore interesting to see if they can be a 
factor in the development of the disease. Here, we assessed the association between 
dioxin-like activity in blood and the risk of breast cancer. 290 women in the ages 41-55 
years who participated in the nationwide survey The Norwegian Women and Cancer 
study (NOWAC) answered questionnaires and donated blood samples in the years 
1999 to 2006. 98 of these were diagnosed with breast cancer. The blood samples were 
analyzed using an AhR-responsive reporter gene bioassay, CALUX, to measure the 
dioxin-like activity. We found no significant association between the dioxin-like activity 
and the risk of breast cancer. These findings are similar to what the majority of other 
studies have found. However, limitations in the sample size and possibly the time of 
blood sampling are important factors when evaluating the results, and more research 





Breast cancer is the most common cancer type in women today and the most 
important reason to death in women under 65 years(1). The last 60 years, there has 
been a doubling in the incidence of breast cancer in Norway (2). Many risk factors have 
been established in the pathogenesis of breast cancer, one of them being that the 
population becomes increasingly older. However, the established risk factors do not 
fully explain the great increase in breast cancer incidence (3). This has made 
researchers look to environmental pollutants, in particular dioxins and dioxin-like 
compounds(DLCs), to assess any associations with breast cancer. Many studies have 
been conducted, but mostly leading to inconclusive results. Animal studies have shown 
significant associations between dioxins and DLCs and different cancers, but it has 
been difficult to assess the same associations in humans. 
1.1  Breast cancer 
Breast cancer is the most common cancer among women today; 22 % of all female 
cancer cases in Norway is breast cancer (2). Over the last decades the incidence has 
increased substantially; the age adjusted incidence have gone up from 60.6 per 100 
000 in 1958-60 to 123.3 per 100 000 in 2011-15 (2). Breast cancer is currently the most 
important cause of death in women under 65 years, thus even more important than 
cardiovascular disease and accidents (2). The 5-year survival rate has in the last 35 
years increased from 69.8% to 89.0%, although the prognosis depends largely on the 
stadium of the tumour at diagnosis (2). In 2013, the 5-year survival was 98.9 % for 
tumours located only to the breast, while it was 25.1 % if there were metastases at the 
time of diagnosis(1). Established risk factors for developing breast cancer are higher 
age(4), hormone replacement treatment during and after menopause(5), early 
menarche(6), late menopause(6), having no children(7), having the first child at an 
older age (35 years)(7), and having a genetic predisposition or having a mother or 
sister with breast cancer (8). Breastfeeding however, lowers the risk (6). Changes in 
people’s life style are also important contributors; smoking, alcohol consumption, 
intake of fatty foods and a decreased activity level are considered factors that increase 
the risk of breast cancer, as well as postmenopausal obesity (7). There are also 
geographical variations in breast cancer, where the incidence and mortality is much 
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greater in industrialized western countries than in the Far East. It is shown that first or 
second-generation migrants from Japan to Hawaii acquire the breast cancer rates in 
the host country, indicating that environmental factors play a more important role 
than genetic factors (7). Even though all of these risk factors are known, they only 
explain 40-50 % of the breast cancer incidences (3). Mammography, a breast cancer 
screening programme for women of 50-69 years, detects more cancers in earlier 
stages and contributes to more tumours being detected, possibly tumours that would 
never have become cancers (9). However, this increased detection of possible benign 
breast tumours does not fully explain the increase in incidences. Nor does the 
increasing age of the population, change in lifestyle or the other established risk 
factors. This, and the fact that animal studies have indicated that several persistent 
organic pollutants are carcinogenic, has made researches look to environmental 
pollutants to assess any associations with breast cancer. 
 
1.2  Dioxins and DLCs 
1.2.1 Dioxins – a specific group of persistent organic pollutants(POPs) 
POPs are organic compounds that persist in the environment, accumulate in organisms 
and exert toxic effects. They are semi-volatile compounds, enabling them to travel long 
distances in the air (10).  Common for all POPs is that they are slowly metabolized or 
degraded and thus being persistent (11). Many POPs have been identified. A group of 
compounds belonging to POPs are polychlorinated dibenzo-p-dioxins (PCDDs) and 
polychlorinated dibenzofurans (PCDFs), commonly called dioxins. They are planar 
tricyclic aromatic compounds, the PCDDs 
contain a dibenzo-1,4-dioxin molecule and 
the PCDFs a a dibenzofuran molecule, each 
with 1 to 8 chlorine atoms attached at 
different positions (Figure 1) (12). There are in total 210 different dioxin congeners of 
the dioxins, 75 PCDDs and 135 PCDFs. The 2,3,7,8–chlorosubstituted congeners 
bioaccumulate the most and are the most toxic congeners, and these make out a total 
Figure 1: The general structures of PCDDs (left) 
and PCDFs (right) (13) 
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of 17 congeners(13). The most toxic dioxin is the 2,3,7,8-tetrachlorodibenzo-p-dioxins, 
or TCDD (13).  
1.2.2 DLCs 
Several chemicals with dioxin-like activity exist, but the most common 
DLCs are polychlorinated biphenyls (PCBs). Biphenyls are molecules 
consisting of two benzene rings connected with a C-C-bond, and in 
polychlorinated biphenyls, one to ten chlorine atoms are attached to 
the rings at different positions (Figure 2) (13). A total theoretical 
number of 209 possible PCB congeners exist, of these, 13 have chlorine atoms only in 
meta- and para-positions, making them similar to dioxins in structure, and gives them 
their dioxin-like toxicity (14).  
1.2.3 Physiochemical properties 
The properties of the different congeners of dioxins and DLCs vary, but in general they 
are highly stable both thermally and chemically and can persist in the environment for 
decades(15). It can take from 7 to 12 years to remove half of the TCDD from the 
human body (16). Mostly, dioxins and DLCs have high boiling points and low vapour 
pressures(13). They are lipophilic and therefore little soluble in water, but resolve well 
in oils, organic solvents and fats (13). In the environment, the congeners are mostly 
found as mixtures and not as single compounds (13). 
1.2.4 Sources of dioxins and DLCs 
Dioxins are unwanted byproducts from chemical processes involving chlorine and 
combustion and have never been produced deliberately or have any known use(11). 
Examples of industries producing dioxins as byproducts are paper manufacturing, 
waste incineration, smelting and the manufacturing of certain types of pesticides and 
herbicides. Natural sources are forest fires and volcano eruptions(17). Dioxins were 
also a by-product of Agent Orange, a blend of two herbicides that the US Army sprayed 
over the forests in Vietnam as a defoliant agent (18). It removed trees and dense 
tropical foliage that the enemy used as coverage during the Vietnam War in 1962 to 
1971 (18). The production of PCBs started in 1929 for use as insulating agents in 
transformer oils and capacitators, as heat transfer agents, as additives in paints, papers 
and plastics, and in sealants for constructing(13). It was sold under names like Aroclor, 
Figure 2: PCB molecule (13). 
9 
 
Fenclor and NoFlamol (14). The production of PCBs was banned in the US in 1979 by 
the US Environmental Protection Agency, and the disposal of PCBs were put under 
regulations(19). Both dioxins and dioxin-like PCBs have been classified as group 1 
carcinogens (20). In 2001, The Stockholm Convention, a global treaty to protect the 
human health and the environment from POPs, was put into force and signed by 152 
countries worldwide (21). The aim was to eliminate dangerous POPs and support the 
transition to other safer alternatives. Initially, 12 POPs were targeted in the 
convention, including some PCBs and dioxins, and today many more POPs have been 
added(21). The convention requires the members to eliminate or reduce the release of 
POPs into the environment(21). Even though many countries have signed the treaty, 
many of them has yet to ratify them, including the US(22, 23). 
1.2.5 Transfer of dioxins and DLCs in nature 
Dioxins and DLCs are highly stable both thermally and chemically, which is the reason 
why they are ubiquitous in the environment today. Degradation mechanisms are slow, 
and intentional degradation requires either high temperature or catalysts(24). Dioxins 
and DLCs may get degraded by sunlight, but is sheltered if attached to particles(25). 
From production, use and disposal, they end up in soil and water where they are 
mainly found bound to particulates because of the low water-solubility(13). From soil 
and water, they reach rivers and oceans, where currents transport them to the Polar 
Regions(26). However, the main transport route is through the air (13). The dioxins and 
DLCs are volatile and have high affinity for air particulates, which enables the 
compounds to spread through the atmosphere. Gravity, precipitation and wind 
currents move the dioxins and DLCs to the ground where it is deposited in soil and 
water. Wind currents transport them to Polar Regions where they get cooled down, 





Figure 3: Transport mechanisms of persistent organic pollutants and bio magnification in organisms (10). 
The lipophilic character of the dioxins and DLCs makes them easily absorbed into organisms 
(13). They get incorporated in smaller organisms, such as plant plankton and animal 
plankton which gets eaten by bigger organisms, which again are eaten by bigger organisms, 
and as the dioxins and DLCs get stored in the fat, it gets accumulated through the trophic 
levels. The highest concentrations are found in the animals highest in the food chain, e. g big 
fish, sea gulls, polar bears, polar foxes, whales and seals (Figure 3) (10).  
 
1.2.6 Human exposure routes to dioxins and DLCs 
Previously, occupational exposure was a major route of dioxins and DLCs to humans 
(27). Studies have shown that workers in factories producing chemicals with TCDD as 
byproducts, such as herbicides, pesticides and trichloropropane, had much higher 
levels of dioxins than the background controls(27). Accidents in these factories would 
also lead to high TCDD levels in the workers doing the cleanups, as well as work 
involving clean-up of PCB waste-sites, PCB disposal activities or work with old products 
containing PCBs, such as x-ray machines, welding equipment, refrigerators, televisions 
and microwaves made before the 1980s (28). Another important source for PCB 
exposure is living close-by incinerators or other PCB-disposal facilities (28). Renovation 
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work involving plaster, paint, and caulk, that contain PCBs also puts people at risk for 
PCB exposure. In Norway there has been little production of PCBs or other major POPs, 
although occupational exposure has been an issue since there has for example been 
production of windows with PCBs and furniture with BFRs(29). However, exposure is 
most likely to be from a combination of earlier import and usage, long-range transport 
and food(30). PCBs and dioxins can get into the human body through breathing and 
skin contact, but the main entrance way is through ingestion(31).  Today, the major 
sources for dioxins and PCBs for the general population are foods such as fish, dairy 
products, eggs and meat(31). The greatest contributor of dioxins and DLCs in the 
Norwegian diet is fatty fish like mackerel, herring, salmon, halibut and trout(32). 
Seagull eggs, cod liver, big halibuts and the brown meat in crabs contain very high 
levels of PCBs and the Norwegian Food Safety Authority recommends limiting the 
intake of these foods, especially for women in childbearing age(32). During pregnancy, 
dioxins and DLCs are transferred to the fetus via the placenta(10), and they can also be 
transferred to the newborn through breastmilk (33). Since breastmilk may be the only 
or predominant food source to the infant, the infant receives high doses of the 
chemical pollutants (34). However, the amount of PCDDs in human milk decreases as 
the breastfeeding period increases, and also decreases with successive breastfed 
children (35). The Norwegian Scientific Committee for Food Safety (VKM) has set a 
Tolerably Weekly Intake (TWI) of dioxins and DLCs to avoid being at risk for damaging 
effects from them(36). TWI is the weekly amount of a substance that can be consumed 
safely throughout a lifetime without risking adverse health effects from environmental 
chemicals in the substances(36). The TWI in Norway is 14 pg TEQ/kg bodyweight/week, 
so for example, an intake of 300-450 g of fish per week, included 200 g of fatty fish, is 
well below the TWI (36). 
 
1.2.7 Trends of levels of dioxins and DLCs in humans 
Since the PCBs and dioxins are lipophilic, they get stored in adipose tissue. An equilibrium is 
established between fatty tissue and the blood, so that the blood serum/plasma gives a 
good indication of the levels of pollutants in the body(37). However, the concentration in the 
blood and adipose tissue in 2017 does not reflect the concentration in the blood and adipose 
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tissue 30 years before, seeing as the levels of POPs in both the environment and the humans 
had a major drop following the restrictions made on the production and use of the POPs 
during the 70s and 80s (38). Biomonitoring studies of POPs and other environmental 
pollutants have been conducted to assess human health risks from exposure to 
environmental contaminants. The Arctic Monitoring and Assessment Programme (AMAP), a 
group working under the Arctic Council, do biomonitoring activities in the eight arctic 
countries; Russia, Canada, Greenland, Norway, Sweden, Iceland, Finland and the Faroe 
Islands. Here they evaluate the conditions of the Arctic ecosystems, identify possible causes 
for changing conditions, detect emerging problems and recommend required actions to 
reduce risks to Arctic ecosystems(39). In 2015 they reported that the levels of most POPs in 
humans had declined since 1979, as seen in measurements done in Norwegian men from 
1979 to 2009 showing a median reduction of 69 % of POP levels in blood serum, including 
PCBs (excluding dioxins) (38). This is consistent with the reduction in emissions following 
international actions to reduce or eliminate production of POPs in the same time period (38). 
Pregnant women in Nunavik, Greenland donated blood samples in 1992 to 2013, and 
overall, levels of POPs in their blood declined by an average of 80 %. These reductions are 
thought to come from international actions eliminating the production and emission of 
POPs, but also from people eating more store-bought food and less traditional food(marine 
mammals and fish), because of governmental recommendations and from cultural 
changes(39). The trend in dioxin levels has not been as extensively studied as for the PCBs, 
but studies show that dioxin levels has followed the same pattern as for PCBs (40, 41). 
Aylward and Hays (41) surveyed literature reporting TCDD levels in samples from the general 
population in the US, Canada, Germany and France. They found a steady and substantial 
decline in TCDD levels from 1979 to 2000 and concluded with an exposure reduction of 95 %. 
Their tentative reasons for these declinations included reductions in open burning practices 
at municipal landfills, homes and apartment buildings; reduction in TCDD levels in herbicides 
used in the United States and subsequent suspension of the use of these herbicides; 
reductions in incinerator emissions due to new regulations and equipment; and lifestyle 
changes such as changes in dietary patterns (41). In Norway, the emission of dioxins has 
been reduced with approximately 70 % from 1995 to 2013 according to the Norwegian 
Environmental Agency(42). Measures to reduce the dioxin load on the environment are 
stricter standards on emission for waste burning industries and other industries. Heating of 
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houses has also been improved in regard to emissions of dioxins, and the goal is to have 
ceased emissions of dioxins in Norway within 2020(42).  
Because of interventions such as the Stockholm Convention, a considerable decline for many 
POPs has been observed. However, the number of organic and inorganic substances that are 
being introduced to the global market are substantial, and over 100 000 substances are 
available in the commercial market(30). These have not yet been identified as toxicants, but 
could be potential hazards to the environment and humans (30). 
 
1.3  Endocrine disruption and health effects of dioxins/DLCs 
Animal experiments and accidents as well as occupational exposure show that dioxins 
and DLCs cause negative health effects. The question is however at what 
concentrations these compounds cause effects in humans from the general population 
that are exposed to low concentrations over the whole lifespan. Dioxins and DLCs 
function as endocrine disruptors,  which means they interfere with normal hormone 
action and can in principle affect any hormonal system containing receptors the 
chemicals can act through (39). In the 2002 report Global Assessment of the State-of-
the-Science of Endocrine Disruptors by the International Programme on Chemical 
Safety (IPCS), endocrine disruptors were defined as “an exogenous substance or 
mixture that alters function(s) of the endocrine system and consequently causes 
adverse health effects in an intact organism, or its progeny or (sub)populations (10). 
Endocrine disruptors can act throughout life just as hormones do, impacting the same 
pathways as the hormones. If the endocrine disruptors are present during 
development, programming of cell and tissue development will be affected and lead to 
permanent effects(39). Endocrine disruption early in life will remain throughout life 
and the tissue will have a different predisposition for disease later in life compared to a 
non-exposed subject(39). For example will exposure to the endocrine disruptor 
bisphenol A to a fetal mice predispose the mouse to prostate-cancer if exposed to low 
levels of estrogen later in life(39). If present later in life, endocrine disruptors can exert 
different effects, which may be transient(39). An example of the endocrine disruptive 
character of dioxins and DLCs is the antiestrogenic effects shown in many studies 
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where TCDD have had toxic effects on ovulation, uterine function, pregnancy, 
endometriosis and embryonic development (43). Furthermore, animal studies have 
shown that dioxins and DLCs can suppress ovarian follicle growth stimulated by 
gonadotropins, inhibit the preovulatory LH-surge and alter the hormone expression 
through the menstrual cycle (43). 
Dioxins and DLCs can exert many other adverse health effects as well. Acute health effects 
have been observed in workers exposed to dioxins, in the form of rashes called 
chloracne(13). This was also seen in the candidate for the presidential election in Ukraine in 
2004, Victor Yushchenko, after being intoxicated with large amounts of TCDD (44). 
Established chronic effects from exposure to TCDD are dermal toxicity, immunotoxicity, 
reproductive effects, teratogenicity, endocrine disruption and carcinogenicity (34). The 
dioxins and DLCs transferred through the placenta can give disrupted neurodevelopment, 
and if present in breastmilk they can lead to transiently damaged liver in the newborn, as 
well as reduced IQ and altered behavior(45). Examples of cancers that may be associated 
with dioxins and DLCs are liver, thyroid, lung, endometrial, breast and testicular cancer(46). 
Dioxins and dioxin-like PCBs are the only POPs that have been classified as Carcinogenic 
Chemicals to Humans by the International Agency for Research on Cancer (47). 
Animal studies have also shown a range of different adverse health effects; exposure of low 
TCDD levels to monkeys during perinatal development led to learning disabilities in the 
monkeys (48). Rodents exposed to dioxins and DLCs developed endometriosis (49), liver 
damages (50), reduced reproductive potential of females, permanently reduced sperm count 
in male progeny and urogenital malformations in both sexes (51). Immunological effects 
have also been seen, such as thymus size reduction, increased susceptibility to infectious 
diseases and suppression of immune functions (52). Neurodevelopmental and other 
developmental disruptions is also established effects of exposure to dioxins and DLCs, as 
seen in developing fish embryos getting craniofacial malformations and neural damage after 
exposure (53). Lethality is also an end-point of dioxins and DLCs exposure to animals (54). 
However, in this study, the endocrine disruptive properties of the dioxins and DLCs are the 




1.3.1 Endocrine disruption 
To understand the endocrine disruptors, it is important to understand how the 
hormonal, or endocrine, system works. The endocrine system consists of organs in the 
body which produces and releases chemical substances, hormones, into the blood, 
where it travels to other tissues and organs and exerts their effects(10).  An example is 
the hormone insulin produced in the pancreas, which induces glucose uptake in 
various cells of the body when released into the blood stream (10). The effects on the 
cells depend on the cell having the right receptor for the hormone. Protein and amine 
hormones can travel freely in the blood, but cannot diffuse into cells, and therefore act 
on receptors outside the cell that forwards the message(10). Some hormones, such as 
steroids, are transported on proteins in the blood and can passively diffuse into cells 
where they connect to intracellular receptors and exert direct effects on changes in 
the cell. The steroid hormones also have receptors on the cell membrane outside the 
cell, and these receptors are considered to be important in how exogenous substances 
influences the cells(10). 
Because the receptors have high affinity for the hormones, the hormones can act at 
very low concentrations and even small amounts of a hormone can initiate important 
effects on the cells. The hormones produce a sigmoidal dose-response curve, where 
small increases in a hormone at low concentrations gives a large increase in effect as 
seen in Figure 4. This is highly important when considering the effects of endocrine 
disrupting chemicals, even at small concentrations. The effect also depends on the 
amounts of receptors on the specific cells. A cell with more receptors will have a dose-





Figure 4: (A) dose-response curve for hormones. (B) more receptors on a cell will shift the curve to the 
left and lead to biological effects at lower concentrations(10). 
However, dose-responses can be more complex because the receptors are activated by the 
hormones in a non-linear fashion, creating a non-monotonic dose-response curve(10). 
Specific hormones can exert maximal effect in the highest and lowest concentrations and 
create a U-shaped dose-response curve. If the maximal effect comes at intermediate levels, 
the curve will be an inverted U(10). The inverted U-shape could be an effect of more than 
one receptor being involved, where one receptor is inhibited and one is activated by the 
same hormone, so that at intermediate levels, there will be maximum activity of both 
receptors combined(10). The non-monotonic curve can also be a result of receptor down-
regulation. Receptors are degraded when the hormones act at high concentrations(10). In 
addition, hormones can exert a toxic effect at high doses, and lead to cell death, which also 
gives a non-monotonic dose-response. Lastly, the affinity of the receptors can change at 
different hormone concentrations, and at high concentrations hormones can bind to other 
receptors as well as their specific receptors, and lead to an increased effect(10). 
Generally, there are two ways for a chemical to act as an endocrine disruptor; directly acting 
on a hormone receptor, or indirectly through affecting hormone delivery(10). When 
designing studies to link human exposures to specific outcomes, the chemical exposure 
needs to be measured at the developmental time-point appropriate for the specific outcome 
that is being assessed(10). Example of endocrine disruptors are PCBs, dioxins, DDTs, 
chlordane and hexachlorobenzene(10). The endocrine disrupting properties of dioxins and 
DLCs are explained later in the text.  
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1.3.2 Estrogen and estrogen receptor 
Estrogen and estrogen receptor(ER) is thought to play an important role in the 
development of breast cancer, although the mechanisms of how estrogens increase 
the risk of breast cancer are not completely clear. Most human breast cancers are 
positive for ER, where chemicals with estrogenic activity can stimulate and chemicals 
with anti-estrogenic activity can inhibit growth(55). The estrogen and estrogen 
receptor is considered to be important for the toxic effects of dioxins and DLCS (56). 
The female sex hormone estrogen is important in the development, maturation and 
functions of female reproductive organs and breasts, and plays an important role in 
the development of secondary female characteristics. It has also an effect on fat tissue 
and the skeletal, vascular and neural system(57). Estrogen is a family of hormones 
circulating in the blood bound to the protein SSBG (sex steroid binding globuline) and 
most of their actions on cells are mediated through Estrogen Receptors(ER) within and 
outside the cell. The estrogen receptor is known in two forms, ERα and ERβ, where 
ERα was discovered first and is the most extensively studied receptor(58). The ER is an 
important component in cell cycle progression and the main effect comes from acting 
on the receptors within the cell, where binding will lead to changes in DNA-
transcription. This is called genomic effects. If the hormone binds to receptors on the 
cell membrane, it will lead to quick responses in the cell, e.g activation of MAP kinases 
and PI3-kinases(57). Activation of PI3-kinases leads to inhibition of apoptosis(59), 
activation of MAP-kinases leads to cell proliferation and cell survival(60). These are 
non-genomic effects. The ER have low specificity and can bind a range of different 
estrogen types and also other chemicals with similar structures (57).  Activation of the 
ER is thought to happen through two main pathways; the “classical” pathway induces 
ER through an agonist, e. g estradiol (E2), and leads to direct interaction between ER 
and DNA and subsequent transcription. In the non-classical way, agonists induce the 
ER to interact with other proteins which then bind to DNA and activate 
transcription(55). As previously noted, many factors related to estrogen production is 
associated with breast cancer, i.e early menarche, late menopause, obesity and use of 
hormone replacement therapy. Santen et al.(61) proposed two possible mechanisms 
for the increased risk; a) breast cell proliferation with simultaneous enhanced rate of 
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mutations stimulated by ER and b) estradiol metabolized into genotoxic metabolites 
leading to increase in DNA mutations (61). 
 
1.3.3 The Aryl Hydrocarbon receptor 
The Aryl hydrocarbon Receptor(AhR) is a ligand-dependent transcription factor part of 
the basic helix-loop-helix(bHLH) family of gene regulatory proteins. The receptor has 
been extensively studied, and it is considered to be the main pathway for the toxic 
effects of dioxins and DLCs as well as other halogenated aromatic hydrocarbons(62). 
These lead to AhR-dependent toxic and biological effects, such as chloracne, cancer 
and immune suppression in humans and hydronephrosis and cleft-palate in mouse 
embryos(63). Other exogenous chemicals have also been identified as AhR-agonists, 
(e.g. 2-(1’H-indole-3-carbonyl)-thiazole-4-carboxyl acid methyl ester), but does not 
lead to the toxic effects seen when dioxins and DLCs activates AhR(64). Although no 
endogenous ligands for the AhR have been identified yet, bHLH factors have in general 
critical roles for embryonic development, and so it is likely that the AhR has a 
physiological function in development. Studies with mice with knockout AhR genes 
were viable and fertile, but developed hepatic defects, indicating a role of AhR in 
normal hepatic development(27). TCDD is considered the most potent activator of the 
AhR of the halogenated hydrocarbons and induces the trancription of CYP1A-
enzymes(65). CYP1A is a group of enzymes comprising of CYP1A1 and CYP1A2 and is 
part of the P450 superfamily metabolizing xenobiotics (chemicals that are foreign to 
the body), like drugs or environmental pollutions. CYP1A enzymes both activates and 
detoxify several environmental carcinogens, such as polycyclic aromatic hydrocarbons 
found in combustion products from cigarette smoke and incineration(66). CYP1A1 are 
mainly extra-hepatic, while CYP1A2 is mainly found in the liver, and both are regulated 
by the AhR(62). The constitutive expression of CYP1A is relatively low in most tissues 
and cells, but treatment with dioxins and DLCs leads to accumulation of AhR in the 
nucleus and subsquent CYP1A-induction(27). When a ligand has diffused into the 
cytosol of the cell, it binds to the AhR, which is bound to two heat shock proteins, 
leading to a conformational change and translocation into the nucleus. Here the 
proteins dissociates and the AhR binds to a nuclear protein called ARNT (AhR nuclear 
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translocator). AhR-Arnt binds to the dioxin or xenobiotic response elements (DRE/XRE) 
on the DNA and induce transcription of the CYP1 gene(62). This is illustrated in Figure 
5.  
 
Figure 5: Activation of AhR leading to DNA transcription and production of the enzyme CYP1A1 (67). 
 
The dioxin- or DLC-induced CYP1A enzymes’ activation of carcinogenic PAHs and 
heterocyclic amines/amides lead to formation of reactive intermediates which can 
cause a wide range of toxicities and cancer(62). Examples are the reactive oxygen 
species(ROS) H2O2, superoxide and hydroxyl radicals(62, 68), which are important in 
promotion of tumor development and progression(69), and catechol estrogen, which 
exerts cytotoxic DNA-damage(70). The majority of the toxic effects of dioxins and DLCs 
are observed weeks after exposure and the adverse effects most likely arise from 
continous and inappropriate expression of specific genes resulting in the delayed toxic 
response(65). The ligand-activated AhR pathway can also alter expression of other 
endocrine receptors and ligands, such as the Estrogen Receptor α in AhR-ER crosstalk, 
which has been observed in human breast cancer cells(64). This crosstalk is induced by 
dioxins and DLCs and inhibits E2-induced responses through the AhR via several 
mechanisms (71). Firstly, the activation of CYP1A1 leads to the metabolism of 
estradiol, depleting intracellular levels of the hormone and yielding hydroxy 
metabolites, that are further oxidized into quinone and semi-quinone forms which can 
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alter DNA(64). If this continues over time, the mutations accumulate and can lead to 
neoplastic transformations(58). Secondly, dioxins and DLCs activate proteasomes 
which degrade ERα. This inhibits effects of the ERα and leads to ubiquitination of 
ERα(64), an important regulation process of the cell cycle(64). Research is being done 
to find AhR-antagonistic drugs that can target the Ah-receptor and inhibit its activity; 
6-MCDF is an identified selective AhR modulator (SAhRM) inhibiting TCDD-induced 
CYP1A1(64).  
 
1.4  Epidemiologic studies on associations between dioxins, DLCs and cancer 
10th of July 1976, an explosion in a chemical manufacture plant in Seveso, Italy resulted 
in the release of high levels of dioxins(72). A retrospective study was initiated in 1996 
where 981 women in the age of 0 to 40 years and living close to the explosion area in 
1976 were included to assess the associations between TCDD and breast cancer (72). 
Blood serum had been sampled short time after the explosion (1976-1981), archived 
and was analysed for TCDD using high-resolution mass spectrometry (HRMS). For some 
of the women (3 %) the blood samples were of insufficient volumes and new samples 
were collected in 1996-97 (72). For the women giving blood samples after 1976, the 
TCDD levels were back-extrapolated to 1976 using a 9-year half-life and first-order 
kinetic model (72). The 15 participants developing breast cancer had TCDD level ranges 
from 13 to 1960 parts per trillion (72). A significant association of TCDD with breast 
cancer was found with a hazard ratio of 2.1 (95% CI 1.0-4.6) (72). 833 women 
participated in the follow-up study in 2008, of these, 66 had now been diagnosed with 
cancer, 33 of which with breast cancer(73). They then concluded with serum TCDD 
being significantly associated with all cancers combined (HR 1.80, 95% CI 1.29-2.52), 
but not significantly associated with breast cancer (HR 1.44, 95% CI 0.89-2.33)(73). 
Limitations in both studies were few breast cancer cases and back-extrapolation of 
serum-TCDD for many of the samples (73).  
Zhang et al(74) conducted a meta-analysis on the association between PCBs and breast 
cancer risk through november 2014. They included 25 studies, involving a total of 6088 
cases and 6778 controls from eight countries and found a positive association between 
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dioxin-like PCBs and the risk of breast cancer, as well as between CYP1a and CYP2b 
inducing PCBs and breast cancer. Recio-Vega et. al(75) measured 20 PCB congeners, 
including dioxin-likes, in the blood serum(year of blood sampling not specified) of 140 
Mexican women, of which 70 were diagnosed with breast cancer, using gas 
chromatography(GC)–electron capture detection. A positive association was seen for 
PCBs and breast cancer, although only for non-dioxin-like PCBs. An increased odds 
ratio was seen for the dioxin-like PCBs, but not significant.  
However, many of the epidemiological studies assessing the relationship between 
dioxins, DLCs and breast cancer have found no associations between dioxin, DLCs and 
breast cancer(76-81). Some researchers are of the opinion that IARC’s classification of 
dioxins and DLCs as Class 1 Carcinogens are based on too weak evidence material (76, 
82). Boffetta et al(76) did a critical review of the epidemiologic studies done on 
exposure to TCDD and cancer risk between 1997 and 2010  and concluded that dioxins 
and PCBs should be considered less toxic and carcinogenic then the IARC had 
determined in 1997. Zheng et al (83) investigated the relationship between DDE and 
PCBs and breast cancer by measuring the concentrations in blood serum sampled in 
1995-1997 from women in Tolland County or New Haven county in the US. They used 
GC in analysing the samples(detection method not specified). Their 475 cases were 
incident breast cancer cases, and the 502 controls were randomly selected from 
residents of Tolland county or patients at Yale-New Haven Hospital with newly 
diagnosed benign breast disease or normal tissue (83). They found no major increase 
in breast cancer risk associated with any congeners of PCB, also not for the dioxin-like 
PCBs they tested for, although they only included two DL-PCBs (83, 84). Danjou et al 
(77) estimated dietary exposure among 63,830 French women followed from 1993 to 
2008 in the E3N cohort study. They based the exposure on questionnaires about diet 
history and food dioxin contamination data from a French national monitoring 
program. They found no significant association between breast cancer risk and dioxin 
exposure(77). Reynolds et al (79) evaluated the association between breast cancer and 
dioxins through measuring dioxins in breast adipose tissue in 79 incident breast cancer 
cases and 52 controls, diagnosed with benign breast disease in the mid-1990s. They 
measured the samples by high resolution GC-MS and found no significant associations. 
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Morgan et al(85) did a case-control study of  breast cancer using 403 matched pairs 
from the National Health and Nutrition Examination Survey (NHANES), conducted in 
1999-2004. Blood serum samples were examined for POPs, including PCBs(analysis 
method of measuring PCBs not specified). They found a positive association between 
breast cancer and the non-dioxin-like PCB 138, but not for total-PCBs or dioxin-like 
PCBs. Limitations in the study was a small study population and the use of cross-
sectional self-reported cancer status data. Ward et al(81) investigated the associations 
between organochlorines and breast cancer in 300 Norwegian women using blood 
samples collected in 1973 to 1999 stored in the Janus Serum Bank in Norway. They 
examined organochlorines, including dioxins and PCBs, using high resolution GC-MS 
and found no associations on elevated breast cancer risk with these chemicals. 
However, they did not include the most toxic dioxin, TCDD, in their results because of 
too low detection rates.  Xu et al(78) did a meta-analysis on the associations between 
dioxin and cancer incidence and mortality in July 2015. Within this study they 
conducted subgroup analysis according to cancer subtypes, including breast cancer. 
They reviewed 12 different studies assessing the exposure to dioxins, and in total they 
had a number of 3768 cases and found no significant risk for breast cancer(78). Mouly 
and Toms evaluated 14 case-control studies and one cohort from 2006-2014 to 
summarize and integrate the risk of breast cancer following environmental exposure to 
POPs, other than DDT(86). 8 of the studies considered the effect of PCB exposure, both 
non-dioxin like and dioxin-like, measuring PCB in serum or plasma, one study 
measuring PCB in adipose tissue. They found inconsistent and inadequate evidence to 
conclude with any certain associations with breast cancer (86). They pointed out the 
weakness of many of the studies having examined the exposure to POPs after the time 
of diagnosis, possibly overlooking exposure at critical vulnerable windows in the 
females’ lives where the breast could be more susceptible to endocrine disruption, 
such as in-utero, puberty, pregnancy or postpartum. Also, the studies had focused 
more on individual chemical compounds, possibly missing effects from chemical 





1.5  Quantifying exposure to dioxins and DLCs 
1.5.1 Assessing dioxins and DLCs in humans 
It is a challenge to correctly assess the concentrations of all dioxins and DLCs in blood, 
since concentrations are low and there is a large number of relevant compounds. 
Furthermore, one snapshot might not be a good estimate of lifetime exposure or 
earlier exposure at sensitive time windows like the in-utero period and early life. At the 
same time individuals may not know that they are exposed, nor to what degree, so 
asking questions concerning exposure is of little value. A way of measuring current or 
former exposure is to ask questions about profession, place and length of residency 
and assessing other activities, and comparing with historical data or area 
measurements of the level of pollutants. However, grouping of work titles, area 
measurements and indirect exposure can lead to the exposure of an individual being 
assessed incorrectly, because the actual exposure degree depends on the individual’s 
experience and activities(87). An easier way to assess an individual’s exposure is using 
biomarkers. Tissues or blood can be used to extract chemical pollutants and thereby 
measure the internal dose in humans(87). An important factor to take into account 
when assessing the levels of dioxins and DLCs in individual women is that these 
compounds are transferred through the placenta and through breastfeeding, thus 
concentrations are lower in a woman after pregnancy and a period of 
breastfeeding(33, 88). Therefore, women having had many children and breastfed for 
many months may have lower levels of dioxins and DLCs than women not having any 
children, even though they have been exposed for the same dioxin and DLC levels(33). 
Age is also a highly relevant factor to be taken into account when comparing dioxin 
and DLC levels in individuals, as an older person most likely will have accumulated 
higher concentrations through a longer lifetime(4). 
1.5.2 GC-MS and CALUX bioassay 
The golden standard for analyzing dioxins and DLCs is the gas chromatography 
combined with mass spectrometry (GC-MS). Gas chromatography separates the 
chemical compounds of a mixture(89), and the mass spectrometry determines the 
mass of the separated compounds(90). Using these two methods in combination gives 
a high certainty of the results(90). In biological samples, isotope-dilution high-
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resolution gas chromatography/high-resolution mass spectrometry (HRGC/HRMS) is a 
very sensitive and specific technique to quantify the concentration of pollutants in the 
samples(91). The concentrations of the different dioxins and DLCs are weighted in 
regard to their TEF-values and then added up to get a TEQ-value (TEF and TEQ are 
explained in the next paragraph)(92). This is however an expensive and time-
consuming technique, and requires large volumes of samples(92). Therefore, other 
techniques have been developed to analyze dioxins and DLCs, and in this study an AhR-
dependent recombinant bioassay has been used to estimate the total dioxin-like 
toxicity/activity in human serum. The method is based on dioxins and DLCs activating 
the Ah-receptor, which is the main mechanism of action of these compounds. The 
advantage of measuring activation of AhR compared to measuring concentrations of 
the different compounds is that the possible supra-additive or antagonistic 
interactions between the compounds in the mixture can be accounted for(93). The 
bioassay used in this study was the CALUX® (Chemical-Activated Luciferase gene 
eXpression) bioassay.  It involves dioxins and DLCs activating a firefly luciferase through 
the AhR pathway gene in cultured H4IIE cells, an enzyme catalyzing the formation of 
light from ATP and luciferin. The strength of luminescence is linearity related to the 
amount of activated luciferase, and can be quantified by a luminometer(94). TCDD 
concentration standards are analyzed at the same time to give a dose-response curve 
for comparison with the luciferase activity, enabling calculation of TEQ values(Figure 
6)(95). However, the activation of the Ah–receptor is not only done by dioxins and 
PCBs, but also by other substances, such as bilirubin, biliverdin, PAH and 
flavonoids(63). These can activate the AhR without leading to toxic effects, but still 
contribute to the TEQ-value if present(96). The samples therefore go through clean-up 
procedures to separate the contribution from these non-dioxin-like substances and 




Figure 6:  The luminescence from activation of the AhR in H4IIE cells expressed as TCDD-
concentrations(93). 
The advantage of the CALUX bioassay is that it requires lower volumes of serum 
compared to gas chromatography/mass spectrometry, it is less time consuming and it 
is inexpensive(93). Windal et.al.(96) argued that the CALUX bioassay is not a full 
replacement for GC-MS analysis because CALUX is not determining the toxic 
equivalency of a complex mixture directly, but only its relative gene induction potency 
of TCDD. They also observed that often CALUX will give a higher response than what is 
obtained by chemoanalyses(96). However, several studies have found good recovery 
and reproducibility and a highly significant correlation between CALUX-derived TEQ 
and TEQ retrieved from HRGC/HRMS (95, 98). 
1.5.3 Evaluating the toxicity of dioxins and DLCs - TEF/TEQ 
The large number of congeners of dioxins and dioxin-like substances are not found as 
single compounds in the environment and human tissues, but rather as mixtures(13). 
The toxicity of such mixtures is expressed through the Toxic Equivalency (TEQ)(84). The 
Toxic Equivalency uses the most toxic compound, TCDD, as a reference value and 
compares other dioxins and DLCs with it(99). Each congener has a Toxic Equivalency 
Factor (TEF) which indicates the degree of the toxicity compared to TCDD(99). The 
concentration of the different congeners in a mixture are multiplied with their TEFs 
and added up, hereby transformed into equivalent concentrations of TCDD(100).  To 
apply the TEF scheme, there must be a common mechanism of action for the 
compounds involved. For the dioxins and DLCs, binding to the aryl hydrocarbon 
receptor is the initial step. The TEF is determined from in vivo and in vitro studies and 
follows many assumptions, the most elementary assumption being that the 
combination of the congeners are concentration or dose additive(99). The TEF-value 
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does not give the direct toxic response of a compound, but the ability to bind to the 
aryl hydrocarbon-receptor, which in turn is associated with toxic effects. TEF can 
therefore not be used to evaluate effects not mediated through Ah-receptor binding. 
However, most of the biological effects of these compounds are mediated through the 
Ah-receptors. To be included in the TEF scheme, a compound must fulfill three criteria: 
1) show structural relationship to polychlorinated dibenzo-p-dioxins (PCDDs) and 
dibenzofurans (PCDFs), 2) it must bind to the ah-receptor and 3) it must mediate 
biochemical or toxic responses through the Ah-receptor(101). These compounds are 
the 2, 3, 7, 8-substituted PCDDs and PCDFs and dioxin-like PCBs. Many other 
substances fulfill the inclusion criteria of the TEQ-scheme, but have insufficient data to 
define TEF values. The TEF values of the included compounds have been derived 
through scientific evaluation of all available scientific data(99).  
 
1.6  Epidemiologic study designs 
The NOWAC study where our data are extracted from is a population based prospective 
cohort study. A prospective cohort is a design where a specific group of individuals are 
randomly selected and followed through time. The individuals are followed up regularly to 
see if they develop specific outcomes of interest. All the members of the cohort must be at 
risk of developing the outcome at the start of the study. When experimental studies are 
excluded because of ethical or practical reasons, observational studies are good alternatives, 
and the cohort design is considered the best observational design, as seen in the Quality of 
Evidence pyramid in Figure 7 (102). However, the cases cannot be randomly selected and a 
major drawback is that the cohort is followed over a longer period of time, and it can lead to 
a loss-of-follow-up. People in the study can die, migrate or decide to withdraw from the 
study. This can lead to a selection bias. The design also depends on voluntary participation, 
which is not randomly distributed in a study group. Health outcomes and exposure under 
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investigation influences the will to participate. These biases can influence the quality of the 
collected data (102).  
 
Figure 7: Ranking of study designs based on quality of evidence in the quality of evidence pyramid (94). 
 In our study, however, it would not be practical to conduct a cohort design. The NOWAC 
study involves 50 000 women, and it would not be possible to analyze 50 000 blood samples 
for dioxins and DLCs. The case-control is the second best observational study design as seen 
in Figure 7. In a case-control study, cases with the outcome under study are compared to 
controls free of the outcome. A case-control study is by definition retrospective since it 
starts with the outcome and looks back at exposure. However, in our study women were 
selected from a cohort to conduct a case-control study, a so-called nested case-control study 
(103). The advantage of a nested case-control design is that the previous exposure of risk 
factors can be considered without recall bias, because the information has been obtained in 
advance by the cohort study. The design is simple, time efficient and has a low cost. The 
selected cases and controls were compared in regard to exposure of dioxins and DLCs. To 
avoid confounding bias, the controls were selected to match the cases. In our study, each 
case was matched to one or two controls in regard to age. 
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1.7  Statistics 
1.7.1 Logistic regression 
In our research we wanted to study if there was an association between dioxin-like 
activity and breast cancer, by evaluating the data acquired from the blood samples in 
the cases and the healthy controls. If there was a positive association, the women with 
breast cancer would in average have a higher level of dioxin-like activity in their blood 
than the controls. Other risk factors also needed to be taken into account, for example 
smoking, family history of breast cancer and hormone replacement therapy. Since the 
outcome in this study was binary (getting the disease or not), logistic regression was 
used.  
With logistic regression it is possible to calculate the effect a variable has on an 
outcome. The dependent variable only has two values, 1= diagnosed with breast 
cancer, 0 = no breast cancer. In contrast to linear regression, where changes in Y are 
related directly to changes in X, logistic regression calculates how much the natural 
logarithm of the odds of Y changes for every unit change in X. It is then possible to 
calculate the probability that the result = 1 (104). Our cases were matched to the 
controls in regard to age to control for confounding, and so conditional logistic 
regression was used. Other important risk factors for breast cancer were also included; 
age at menarche, parity, age when first child is born, breastfeeding, age at menopause, 
usage of hormone replacement therapy and oral contraception, BMI, having a mother 
with breast cancer, alcohol consumption and smoking status. The impact of each 
variable is calculated and this avoids confounding effects of the other variables(105).  
Odds is the probability for an event to happen in relation to the event not happening. 
The odds ratio is the ratio between two odds(106). 
𝑂𝑑𝑑𝑠 =
𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑔𝑒𝑡𝑡𝑖𝑛𝑔 𝑑𝑖𝑠𝑒𝑎𝑠𝑒
𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑛𝑜𝑡 𝑔𝑒𝑡𝑡𝑖𝑛𝑔 𝑑𝑖𝑠𝑒𝑎𝑠𝑒
 
OR = 
𝑂𝑑𝑑𝑠 𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑔𝑒𝑡𝑡𝑖𝑛𝑔 𝑑𝑖𝑠𝑒𝑎𝑠𝑒
𝑂𝑑𝑑𝑠 𝑢𝑛𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑔𝑒𝑡𝑡𝑖𝑛𝑔 𝑑𝑖𝑠𝑒𝑎𝑠𝑒
 
The odds ratio represents the relative risk of developing a disease. An odds ratio 
greater than 1, means that the risk factor is associated with a higher risk. Is it smaller 
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than 1, the risk factor is considered a protective factor. If it equals 1, there is no 
association (102). Thus, if the confidence interval includes 1, that means there is no 
significant association between variable and outcome. 
In our dataset, the variables were both numerical and categorical, and were not 
normally distributed. 
1.8  Aim 
The aim of this master thesis was to assess whether dioxin-like activity in blood 
plasma, measured by the CALUX bioassay, increase the risk of breast cancer. 
 
 
2. Material and methods 
2.1  The study group 
The Norwegian Women and Cancer (NOWAC) study was started in 1991 and is a 
population based prospective cohort study. The main object of NOWAC is to 
investigate the correlations between internal and external hormones and cancer in 
women, where breast cancer is the most frequently occurring cancer type. 172 000 
women, randomly selected from the Norwegian Central Person Register, in the age of 
30-70 years, have answered questionnaires since 1991 and up to 2006(107). The 
questionnaires handed out included questions involving use of oral contraception and 
hormone replacement therapy, diet, smoking, alcohol consumption, activity level, 
reproductive history, anthropometry and family history of cancer. The questionnaires 
were handed out with an interval of approximately 7 years. The women recruited in 
1991-92 could have answered in total three questionnaires, one initial and two follow-
ups. In 1998, the study became part of the European Prospective Investigation into 
Cancer and Nutrition (EPIC), which is a European cooperation between ten European 
countries(108). 
Since 2006, blood samples have been collected from subjects agreeing to it. At the 
time of blood sampling, detailed questionnaires about current health status were 
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answered by the women. The Cancer Registry of Norway sends annual updates on 
which of the study participants have been diagnosed with cancer (107). 
All the women participating in NOWAC have signed an informed consent. The 
participating women are completely anonymous and the researchers cannot connect 
the results to any individual. The regional ethical committee (REK) for Northern 
Norway has approved all the analyses, including the blood samples in both the NOWAC 
study and this particular study(109). 
 
2.1.1 Our study sample 
From the NOWAC study, blood samples were selected from 98 women, 71 that were 
later diagnosed with breast cancer and 27 that had breast cancer already. To each 
case, two healthy controls were randomly selected, matching the cases on age and 
year of donating blood samples. In the start of the study, the study sample consisted of 
298 women; 98 cases and 200 controls which had never previously been diagnosed 
with breast cancer. The breast cancer diagnosis of the cases was the first primary 
invasive cancer they had gotten, primary meaning that the tumour originated from the 
breast and invasive meant that it infiltrated surrounding tissue or blood. It was 
possible however that they earlier could have had in-situ breast cancer, borderline 
tumour in the ovaries or non-melanoma skin cancer. Blood was sampled from the 
women in 2000, 2001 and 2002. 27 of the cases were diagnosed with breast cancer 1-3 
years before or the same year(1999-2002) as handing in their blood samples. The 
remaining 68 cases were diagnosed 1-6 years after handing in blood samples, between 
2000 and 2006(Table 1).  
Table 1: Time of diagnosis and sampling of blood of the cases. 
 Cases  Year of diagnosis Time blood sample  
Diagnosed before 
blood sample 
27 1999-2002 0-3 years after diagnosis 
Diagnosed after 
blood sample 




Of the controls, three women developed breast cancer 7 to 13 years after giving the 
blood samples.  These were excluded from the study. Five more controls were 
excluded because they were missing matching cases. Summed up, the study sample 
consisted of 290 women, each case matching with two controls in regard to age and 





2.2  Analysis of blood serum 
The samples that were collected from the cases and controls were stored frozen and 
thawed before preparation. While in the freezer, some of the glass tubes had broken 
and a few samples were lost in the thawing because of this.   
Dioxins and DLCs were extracted from the 298 plasma samples using a liquid-liquid 
extraction. In short, denatured alcohol was added to the plasma sample and the 
mixture was extracted thrice with hexane. The organic phases were combined and 
evaporated under vacuum. The resulting extract was purified on an acid-silica column 
and reconstituted with 5 μL dimethyl sulfoxide. We determined total DLC 
Start: 98 cases, 200 controls
exclusion of controls getting 
breast cancer after handing 
in blood samples (n=3)
exclusion of controls lacking 
case (n=5)
98 cases, 192 controls
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concentrations in samples extracts using an arylhydrocarbon receptor (AhR) reporter 
gene assay according to the procedure described in (93). The bioassay is based on the 
expression of the firefly luciferase in H4IIE.Luc cells resulting from the activation of the 
AhR pathway by dioxins and DLCs.  H4IIE.Luc cells (kindly donated by A. Brouwer, 
BioDetection Systems B.V., Amsterdam, The Netherlands) were obtained by 
transfecting rat hepatoma H4IIE cells with the luciferase reporter gene plasmid 
pGudLuc1.1. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) equivalents (TCDD-EQ) 
concentrations in plasma extracts are interpolated from a TCDD standard curve. The 
limit of detection is 30 pg TCDD-EQ/L, corresponding to approximately 5 pg TCDD-EQ/g 
lipids 
 
2.3  Exposure variables and covariates 
To assess the association between dioxin-like activity in blood and breast cancer, the 
statistical software Stata 14 was used. Before building the statistical model, the 
variables needed to be organized. The TEQ-value was considered first by dividing it 
according to the median. When looking at the histogram of the distribution of the TEQ-
values in Figure 8, it is seen that the line at the median (115.0 pg/L) divides the groups 
so that the TEQ-values in each group would be very similar. Many of the women with 
low TEQ-values would be considered alongside with women with higher values. 
Therefore, a group was made where the TEQ-values were divided into quartiles where 
the 1st to 3rd quartiles where one group, and the 4th quartile accounted for the second 
group. This is seen as the second line at 209.3 pg/L in Figure 8. This gave a better 




Figure 8: Histogram showing TEQ-values for the cases and controls. The red stripes show the 
frequencies at the median TEQ-value 115.0 pg/L and 75-percentile TEQ-value at 209.3 pg/L. 
 Furthermore, 36 women had not answered the question if they had had a mother 
with breast cancer. These were categorized as not having a mother with breast cancer 
in the modelling. The menarche category was grouped into above or below 13.2 years, 
which is the average age of menarche in Norway(110). In this variable two women 
were missing. The variable “Hormone replacement therapy” was made through using 
the questionnaire which was handed the women when taking their blood samples, in 
combination with former questionnaires to obtain the most accurate answers. The 
menopause group was categorized into three groups, pre, post and others, where 
others included unknown, hysterectomy and hormone replacement therapy and under 
53 years of age. Since all case-control pairs were matched on age, age was not an 
influencing factor to the model. Alcohol intake was divided according to below or 
above median (2.0 g/day) of the study group. BMI was divided into three groups; 
below 25 kg/m2, 25 to 29.9 kg/m2 and above 30 kg/m2, corresponding to normal 
weight, overweight and obesity respectively (111). Two subjects had missing values in 
the BMI-group. The age at which the women got their first child was divided according 
to the median at 24 years. 19 women were missing in this group. Breast feeding was 
34 
 
divided into 0, 1-12 months, and above 12 months. 20 women were missing from this 
category, but when comparing with the total amount of children-groups, it was seen 
that the 18 without children belonged to the 20 missing. Therefore, only two women 
were missing in this group. 
2.3.1 Statistical analysis 
Univariable conditional logistic regression in Stata 14 was used to obtain the OR for 
each covariate. This was done using the crude sample where n=290. The result is seen 
in Table 2. The covariates with p-values significant at 25 %-level were included in a 
multivariate conditional logistic regression model. These covariates were menopause, 
parity, mother with breast cancer, BMI grouped in three categories, smoking status 
and alcohol intake. To work out the most optimal multivariate model, the recipe of 
logistic regression modelling in Veierøds Medical Statistics, pages 110-114 (112). The 
six significant covariates were inserted into the model and dropped one by one to find 
if they were confounding the results. The insignificant covariates were then added 




3.1  Study population characteristics 
Our study group consisted of 290 women (mean age 48.6 ±3.89 years), 89 of these had 
been diagnosed with breast cancer. 27 of which were diagnosed before giving blood 
samples. For each case two age-matched controls were selected. Blood samples were 
drawn from the participating women, and TEQ-values were obtained. The histograms 




Figure 9: Histogram showing the TEQ-values for cases and controls.  
The distribution of cases and controls by age, TEQ-value, age at menarche, parity, age when 
first child is born, breastfeeding, age at menopause, usage of hormone replacement therapy 
and oral contraception, BMI, mother with breast cancer, alcohol consumption and smoking 
status are presented in Table 2. Both the cases and controls had an average menarche age of 
13.3 years, had their first child at an average age of 24 years and breastfed for an average of 
14.6 months. 33.8% of the women used or had used oral contraceptives and 42.8 % used or 
had used hormonal replacement therapy. 47.9 % of the women were pre- or perimenstrual 
and 29.3% were postmenopausal. The mean BMI was 24.7 kg/m2 in the whole group, and 
mean alcohol consumption was 3.3 g/day. The TEQ-values did not differ significantly 
between the cases and controls, as seen both in the histograms in Figure 9 and the numbers 
in Table 2; the average value was 279.3 pg/L in the cases and 298.7 pg/L in the controls. 
Furthermore, there was no difference in proportion of people in the 4th quartile of TEQ-
values between cases and controls. From Table 2 it is also seen that the highest 
concentrations of TEQ are among the women in the control group. 
Having a mother with breast cancer gave a significantly higher risk of breast cancer; the odds 
ratio was 3.2 (1,18- 8,87). Furthermore, being a current smoker was associated with a higher 




Table 2: Study population characteristics. 
Variable Total(n=290) Case(n=98)  Control(n=192) OR(95%CI) p-value* 
TEQ-value (pg/L) 
Mean (std.dev) 292,1 (487,7) 279,3 (433,5)  298,7 (514,2)   
Median(max-min) 115,0(28,1-2346) 111,5(30-2059)  122,7(28,2-2346)   
TEQ-value (pg/g serum lipids)a 
Mean 50,4 (84,1) 48,2 (74,7)  51,5(88,7)   
Median(max-min) 19,8 (4,8-404,5) 19,2(5,2-355)  21,2(4,9-404,5)   
75-percentilb, n (%) 
<209.3 pg/L 218 (75) 71 (72.5)  147 (77.6) Reference  
≥209.3 pg/L 72 (25) 27 (27.6)  Reference 1,28 (0,73 - 2,23) 0,38 
Age at menarche (years)c, n (%) 
<13,2 161 (55.5) 50(51.0)  111 (57.8) Reference  
≥ 13,2 127 (43,8) 46 (46.9)  81 (42.2) 1,30 (0,80 - 2,13) 0,30 
Age at birth of first child (years)c, n (%) 
<24 126 (43.5) 44 (44.9)  82 (42.7) Reference  
≥ 24 145 (50.0) 48 (49.0)  97 (50.5) 0,90(0,54-1,50) 0,70 
Parity, n (%)       
0 18 (6.2) 6 (6.1)  12 (6.3) 1,09(0,40-2,97) 0,87 
 1-2 152(52.4) 46(46.9)  106 (55.2) Reference  
>2 120(41.4) 46(46.9)  74 (38.5) 1,39(0,85-2,27) 0,19 
Breastfeeding (months), n (%)c 
0 29 (10.0) 9 (9.2)  20(10.4%) Reference  
 1-12 133(45.9) 43(43.9)  90(46.9%) 1,06(0,45-2,49) 0,89 
>12  126(43.5) 46(46.9)  80(41.7%) 1,26(0,53-2,98) 0,60 
Menopause, n(%) 
Pre/peri 139(47.9) 50(51.0)  89 (46.4) Reference  
Postmenopausal 85 (29.3) 24(24.5)  61 (31.8) 0,47(0,20-1,12) 0,09 
Othersd 66 (22.8) 24(24.5)  42 (21.9) 0,92(0,45-1,92) 0,83 
Hormone replacement therapy, n(%) 
Never 166(57.2) 58(59.2)  108 (56.3) Reference  
Former/Current 124(42.8) 40(40.8)  84 (43.8) 0,89(0,52-1,54) 0,68 
Oral contraception, n(%) 
Never  98 (33.8) 31(31.6)  67 (34.9) Reference  
Former/Current 192(66.2) 67(68.4)  125 (65.1) 1,15(0,68-1,92) 0,60 
Mother with breast cancer, n (%) 
No  271(93.5) 87(88.8)  184(95.8) Reference  
Yes 19 (6.6) 11(12.4)  8 (4.2) 3,23(1,18-8,87) 0,02 
Body mass index (kg/m2)c, n (%) 
BMI<25 181(62.4) 56(57.1)  125 (65.1) Reference  
BMI 25-29,9 75 (25.9) 31(31.6)  44 (22.9) 1,59(0,89-2,82) 0,09 
BMI ≥ 30 32(11.0) 10(10.2)  22 (11.5) 1,19(0,51-2,75) 0,68 
Smoking status,n(%)      
Never 99 (34.1) 26(26.5)  73 (38.0) Reference  
Former 115(39.7) 40(40.8)  75 (39.1) 1,51(0,84-2,71) 0,17 
Current 76 (26.2) 32(32.7)  44 (22.9) 1,94(1,04-3,63) 0,04 
Consumed alcohol (gr/day), n (%) 
<2.0 gr/day 147(50.7) 56(57.1)  91 (47.4) Reference  
≥ 2.0 gr/day 143(49.3) 42(42.9)  101 (52.6) 0,69(0,42-1,12) 0,13 
 
*obtained from univariate conditional logistic regression, n=290. 
aLipid normalized values obtained by using 0.58% fat content in the blood (113). 
bvalues obtained by dividing the TEQ-value according to the 75-percentile  
ccategory with missing values 
dThe groups others contain the women that are unknown, got hysterectomy, or uses hormone replacement therapy 
and are under 53 years of age. 
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The odds ratios of the TEQ-value obtained from the conditional univariable and multivariable 
logistic regressions are shown in Table 3. The crude, adjusted and fully adjusted ORs did not 
differ much and were also not significant in relation to breast cancer. In the multivariable 
model, having a mother with breast cancer was the only variable significantly associated 
with breast cancer.  
Table 3: Odds ratio and confidential intervals for the TEQ-value with and without adjusting for covariates, 




Crude  1,28(0,73–2,23) 0,39 
Adjusted 1,33 (0,75-2,35) 0,33 
Fully 
adjusted 
1,42(0,75 –2,67) 0,28 
 
a  Not adjusted. n=290. 
bAdjusted for having a mother with breast cancer. n=288 
b Complete case analysis n=286. OR adjusted for covariates age at menarche, mother with breast cancer, 
BMI, smoking status, alcohol consumption, hormone replacement treatment, oral contraception use, 
age at menopause, breast feeding, age when getting the first child and parity. 
 
Univariate and multivariate conditional logistic regression was done to the study sample 
after excluding the 27 cases that were diagnosed before blood sampling, and their 
respective controls (Appendix 1). With the 27 removed, alcohol consumption became a 
significant risk factor for breast cancer, but the p-value of the TEQ-value did not change 
significantly.  
The TEQ-value was normalized from the wet weight concentration to a lipid weight 
concentration, to enable comparison with TEQ-values derived in other studies(Table 4) 
(113). The mean/median lipid weight concentration was 19,8 pg/g serum lipids. Total 
lipids were not measured in the samples used in this study, instead we used the 
average lipid concentration (0.58%) in a comparable group of women from 





In this study, we assessed the dioxin-like activity in blood from 98 breast cancer cases 
and 192 age-matched controls. Our study does not support an association between 
dioxin-like activity and breast cancer. Of the 98 women diagnosed with breast cancer 
in this study, 27 donated their blood samples 1-3 years after being diagnosed with 
breast cancer. The other women donated blood up to 6 years prior to breast cancer 
diagnosis. As one criteria for causality is that the exposure have occurred prior to the 
outcome, we conducted a sensitivity analysis where these 27 samples and their sub-
sequent controls were excluded. This did however not make a difference and gave no 
significant association between TEQ-values and breast cancer risk. Further, since the 
cases and controls were matched not only on age, but also on year of blood sampling, 
we made sure that the declining concentrations of these compounds in human blood 
over the recent decades did not influence the findings. 
Our findings of no association between breast cancer and dioxin-like activity is in 
agreement with what the majority of other studies have found, such as the meta-
analysis conducted by Xu et al. (78) and the case-control study on Norwegian women 
by Ward et al(81). However, from the literature search that was done in this study, no 
other studies were found that had investigated the association between dioxin-like 
activity in blood serum and breast cancer using the CALUX bioassay. Also, many of the 
other studies have focused on non-dioxin-like PCBs, or only including the PCBs with 
lower TEF-values. Some also estimated the exposure from questionnaires and 
geography, being less accurate than measuring the dioxins and DLCs within the 
individuals.  
Having a mother with breast cancer and being a current smoker was found to give an 
increased risk of breast cancer. These findings are in agreement with other 
literature(7, 114). However, we did not detect any association between the use of 
hormone replacement therapy for menopause or parity and breast cancer, risk factors 
that are well established(7). The reason for this could be that the study sample is 
relatively small, which may have given a low statistical power. As most study 
participants have low and comparable TEQ-values, a large study group is required to 
detect small differences in concentrations between cases and controls. 
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In a review, TEQ-values from studies that had collected blood samples approximately 
the same years as us and also used AhR-responsive reporter gene bioassays were 
compared(Table 4). These studies contained both highly exposed groups and groups 
from the general population, and some had mixed genders and some only women or 
only men. When comparing lipid-adjusted TEQ-values, our group has a lower median 
TEQ-concentration than most of the other studies. This influences the interpretation of 
the results. If extremely low concentrations were seen, one could expect a different 
association between TEQ and breast cancer in a highly exposed population, given a 
linear dose-response relationship between TEQ and breast cancer. Smaller variations 
make it more challenging to detect an association. However, if the NOWAC women 
had had very high concentrations compared to other groups, it would be less likely 
that the dioxin-like activity would have had an effect on breast cancer in a less exposed 
population. However, if the endocrine disrupting mechanisms of the dioxins and DLCs 
were actually explained by a non-linear dose-response relationship, e.g exert the most 
toxic effects at very low and very high concentrations, giving a U-shaped dose-
response relationship, the relationship at different concentrations would be more 
challenging to compare. Also, the effect from the dioxins and DLCs could be present 
only at very high concentrations. Therefore, our lack of association with breast cancer 




Table 4: The lipid-adjusted TEQ-value from our study compared to TEQ-values from other studies (104).  
 AhR mediated activity 
TEQ pg/g serum or plasma lipids 
    
Study Median Range Age(years) Gender Known 
exposure 
n Population (year of blood 
samples collected) 
Our study 
19,8 4,8-404,5 41-55 Female Gpa 290 Norwegian women (1999-2006) 
Medehouenou et al (93) 
9.7 <5–144 18–74 Both Gpa 874 Inuit of Nunavik, Canada (2004) 
Long et al (115) 
197 38–1188 23–47 Male Gpa 70 Inuit of Greenland (2002-2004) 
Dhooge et al (116) 
11.9 NA 20–40 Male Gpa 101 Antwerp and Peer, Belgium 
(1999-2000) 
Ayotte et al (117) 
93 37–287 25–75 Both Mixed 40 Coastal communities, Canada 
(after 1992) 
Warner et al (92) 
25.4b 0–128 20–49 Female High 32 Seveso, Italy (1998-1999) 
Koppen et al (95) 
35.0b 12–65 50–65 Female Gpa 47c Antwerp and Peer, Belgium 
(1999) 
Pauwels et al (118) 




cPooled samples originating from 200 individual women 
 
4.1  Strengths 
The strength in our study is that it is a nested case-control study, the participating 
women have been followed up through many years so there should be no recall bias as 
most of the information from the questionnaires was collected prior to breast cancer 
diagnosis. Also, the majority of blood samples were collected prior to clinical diagnosis, 
thus we have the possibility to measure the exposure occurring prior to the outcome. 
The cases are matched to the controls in regard to age and we have also taken into 
account known risk factors for breast cancer, to avoid confounding of our results 
The dioxins and DLCs were measured through the AhR-dependent recombinant 
bioassay, which measures the dioxin-like activity through activation of the Ah-
receptor. Even though this excludes potential effects exerted by the dioxins and DLCs 
through other pathways, the AhR-pathway is the main mechanism and should be 
accountable for the dioxin-like toxicity(62). The results are then given as toxic 
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equivalency factor, in other words, explained as if all the activation was related to the 
toxicity of TCDD. The advantage with this method is that it does not focus on the 
concentrations of different congeners, but rather the total effect of all the congeners 
combined. Some congeners may function as agonists and some as antagonists, and 
when assessing the activation done by the mixture, it is possible to see the additive 
effect. This makes more sense than measuring concentrations of compounds, if 
hypothetically the compounds in the mixture suspected to induce changes leading to 
breast cancer actually equalized each other, or oppositely, enhanced each other’s 
effects. However, the results can potentially be affected by contamination of natural or 
synthetic AhR ligands such as bilirubin and flavonoids, and other polyaromatic 
hydrocarbons. These ligands typically bind to AhR without leading to toxic effects. 
Most likely, most of them have been removed in the purification of the blood samples 
in the lab. Several studies have found good recovery and reproducibility and a highly 
significant correlation between CALUX-derived TEQ and TEQ retrieved from 
HRGC/HRMS, especially when comparing two groups, such as in our study (95, 98). 
4.2  Limitations 
Despite not showing any correlations, our study cannot conclude that dioxins and DLCs 
are not risk factors of breast cancer. The greatest limitation may be the fact that the 
exposure is measured only a few years before time of diagnosis. We measured the 
serum levels of dioxins and DLCs in the years 1999-2002, a few years before (and after) 
diagnosis. Considering the decline in levels of dioxins and DLCs the last decades, it is 
reasonable to assume that the levels of dioxins and DLCs in the women have been 
higher when they were younger and exposed to higher concentrations in the 
environment. It is hard to assess the etiological relevant time for exposure in relation 
to development of cancer. Cancer is a disease coming from damage to the DNA in a 
cell, leading to disruption of a cells normal cycle, where the cell can continue to grow 
and avoid being destroyed. The development of such a disease is complex and factors 
contributing to the development can be present at different stages and at many years 
before the cancer can be detected. Measuring the dioxins and DLCs at 1-6 years before 
(or 0-3 years after) breast cancer was detected, showed that the dioxins and DLCs 
were present in the women, but not reflecting exposure many years back in time, 
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possibly at more relevant times. Hence, it is not possible to say anything about 
exposure at more vulnerable times, such as fetal stage, childhood, puberty or 
menopause. This is important when considering our lack of association.  
In our study, we have focused only on the effects the dioxins and DLCs exert through 
the Ah receptor, excluding effects from other POPs that could potentially create a 
harmful cocktail when combined with the dioxins and DLCs. Dioxins and DLCs only 
constitute a fraction of the total amount of POPs humans are exposed to and it may be 
that the dioxins and DLCs are more harmful in combination with other POPs. However, 
it is difficult to assess the effects of many different chemical compounds combined, 




We found no evidence of an association between dioxin-like activity in blood and 
breast cancer in this study. There was no difference in dioxin-like activity in blood 
between cases and controls. This finding is in line with many studies, although no 
studies equal to ours. Leaving out the 27 cases that were diagnosed before giving 
blood samples did not make a difference on the results. We did however find a 
significant association between smoking and breast cancer, and having a mother with 
breast cancer and breast cancer. No associations were found between other known 
risk factors and breast cancer. It was also seen that the participants in this study had 
lower lipid-adjusted TEQ-concentrations than those in many other studies. Our study is 
a snapshot of the dioxin-like activity and breast cancer. For these reasons, this study 
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Table 5: ORs from univariable conditional logistic regression, cases diagnosed before blood sampling 
excluded, n=263 
 OR(95% CI) p-valuea 
TEQ75, quartilesb   
1st-3rd Reference 1,0 
4th 1,25 (0,65 – 2,39) 0,67 
Age at menarche, yearsc   
<13,2 Reference 1,0 
≥13,2 1,05 (0,58 – 1,88) 0,88 
Age at birth of first childc, years  
<24 Reference 1,0 
≥24 0,85 (0,47 – 1,53) 0,59 
Parity, number of children   
0 0,80 (0,21 – 3,01) 0,74 
 1-2 Reference 1,0 
>2 1,57 (0,89-2,76) 0,12 
Breast feedingc, months   
0 Reference 1,0 
 1-12 1,45 (0,50 – 4,21) 0,49 
<12 1,89 (0,64 – 5,58) 0,25 
Menopause   
pre/peri Reference 1,0 
Post 0,97 (0,34 – 2,53) 0,88 
Othersd 0,80 (0,34 – 1,85) 0,60 
Hormone replacement therapy   
Never Reference 1,0 
Former/current 0,79 (0,42 – 1,48) 0,46 
Oral contraception use   
Never Reference 1,0 
Former/current 1,25 (0,68 – 2.32) 0,47 
Mother with breast cancer   
No Reference 1,0 
Yes 3,84 (1,16 – 12,70) 0,03 
Body mass indexc, kg/m2   
<25 Reference 1,0 
25-29,9 1,78 (0,92 – 3,46) 0,09 
≥30  1,23 (0,43 – 3,53) 0,70 
Smoking status   
Never Reference 1,0 
Former 1,56 (0,78 – 3,13) 0,21 
Current 2,10( (0,99 – 4,45) 0,05 
Alcohol intake, gr/day   
<2 Reference 1,0 
≥2 0,48 (0,27 – 0,87) 0,02 
aobtained from univariate conditional logistic regression, n=263. 
bvalues obtained by dividing the TEQ-value according to the 75-percentile  
ccategory with missing values 
dThe groups others contain the women that are unknown, got hysterectomy, or uses hormone replacement therapy 





Table 6: Odds ratios and confidential intervals obtained from multivariate conditional logistic regression, 







Crudea 1,25 (0,65-2,39) 0,50 
Adjustedb 1,18 (0,61–2,27) 0,63 
Fully 
adjustedc 
1,25 (0,58-2,70) 0,57 
 
a  Not adjusted for any covariables. 
bAdjusted for the only variable being significant in the multivariate regression; alcohol groups. 
c Complete case analysis n=286. OR adjusted for covariates age at menarche, mother with breast cancer, 
BMI, smoking status, alcohol consumption, hormone replacement treatment, oral contraception use, 













Summary of article evaluations 
 
Reference: Aylward, L. L. and S. M. Hays (2002). "Temporal trends in human TCDD body burden: Decreases over three decades and 





Aim Material and methods Results Discussion/comments 
Estimate historical (ca. 1970), 
current, and likely future of 
"background" TCDD body 
burdens in the general 
population.  
Study design: Unsystematic literature 
review 
Method: They surveyed literature for 
studies reporting levels of TCDD in fat 
tissue or blood samples of the general 
populations. The data from the 
various studies were plotted versus 
the median year of sampling to 
evaluate the temporal trend in lipid-
adjusted TCDD levels in the general 
population. Modelling was performed 
for changes in body burden as a 
function of intake. 
 
 
Mean lipid-adjusted TCDD 
levels from general population 
samples in the US, Canada and 
western Europe.  
 
Strengths: Consistent findings from study groups involving 
over 2800 individuals. 
Weaknesses: There is no information on how they have 
conducted the literature search. The population of the 
different studies have not been defined. A lack of data on total 
TEQ body burdens from before the 1980s. The data compiled 
and analyzed do not constitute a statistically representative 
sampling of general population body burdens over time. The 
data are samples of opportunity collected in various locations 
and for various purposes, and they represent groups of 




Mean lipid levels of TCDD 
exhibited a steady decrease by 
nearly a factor of 10 over 30 
years from 1970 to 2000. 
Land 
The United States, Canada, 
Germany, and France 




Reference: Warner, M., et al. (2005). "Dioxin-Like TEQ of women from the Seveso, Italy area by ID-HRGC/HRMS and CALUX." journal of Exposure Analysis and 






Aim Material and methods Results Discussion/comments 
Characterize current 
background exposure to 
dioxins and DLCs in the 
Seveso area of Italy, and 
examine the correlation of 
these measurements with 
the CALUXs by XDS 
bioassay measure of TEQ 
with high resolution gas 
chromatography/mass 
spectrometry. 
Study design: Cross sectional 
Reruitment of participants: 
Participants were women from 
20 to 49 who participated in an 
endometriosis case-control 
study at Desio Hospital, Italy, 
about 25km north of Milan. 
These women have been and 
are exposed to significant 
amounts of TCDD. A total of 78 
women participated. 
Criteria of inclusion: the 
participating women had to be 
20–50 years old and scheduled 
to undergo laparoscopy for 
pelvic pain, infertility, tubal 
ligation, or adnexal/uterine 
mass at the Hospital of Desio, 
Italy between July 1998 and 
December 1999. 
Method: The women were 
interviewed by trained nurse-
interviewers about 
sociodemographics, personal 
habits, and reproductive 
history. A 70-ml blood sample 
Main findings: Dioxin and DLC concentrations in the women from the Seveso area 
were comparable to body burdens reported in other background-exposed 
populations in industrial nations. Also, the distribution of congeners was similar 
to that reported for other North American and European countries. No significant 
correlation between CALUX-TEQ and total TEQ or any TEQ measure derived from 
HRGC/HRMS data was found. 
Other findings: Age was a significant predictor of Total TEQ in this Italian sample, 
consistent with that reported by others. 
 
 
Check list cross sectional study: 
1. Was the population well defined? yes 
2. Was the study group representative for the 
population? It was representative for women of 
the age 20-49 years in the same area. 
3. Is it explained if and how the responders differ 
from the non-responders? No 
4. Is the answering percentage high enough? No 
data given. 
5. Was the data collection standardized? Yes 
6. Are objective criterias used for evaluating 
outcomes/exposure? Yes, data from blood 
sample analyzes. 
7. Have adequate methods been used in the data 
analysis? Yes. HRGC/HRMS analyzes and 
bioassays were performed on an independent 
basis. 
Strengths: The study uses both the golden 
standard HRGC/HRMS to assess the TCDD levels 
in the blood serum, as well as a bioassay. 
Extensive cleanup methods were used before 
analyzes. 
Weaknesses: A relatively low study sample. Not 
studying women older than 49 years old. 
Conclusion 
The two measures were 
not significantly 
correlated. More 
validation of the CALUX 
bioassay with larger 
sample volume is needed 
before application as an 
exposure measure in 
large-scale epidemiologic 





Land was taken. 15 mL of this was 
examined by HRCG/HRMS. 32 
plasma samples (4ml) were 
sent to XDS CALUX bioassay 




What did the writers discuss? That their findings 
of the CALUX only have a moderate sensitivity 
(20–54%) and that larger sample volumes may 
be necessary in the analyses. They argue that 
others have done a less thorough cleanup of the 
samples than them, possibly yielding a falsely 
higher TEQ and sensitivity. 
Other literature supporting their findings? 
Several studies supported the findings of TCDD-
levels, also compared to age, but not supporting 
their findings in bad correlations between 
HSGC/HSMS. 
Italy 








Reference: Nøst, T. H., et al. (2013). "Persistent Organic Pollutants in Norwegian Men from 1979 to 2007: Intraindividual Changes, Age–Period–Cohort 





Aim Material and methods Results Discussion/comments 
Examine the association 
between individual serum 
TCDD levels and breast 
cancer risk in women 
exposed to high levels of 
TCDD after an industrial 
explosion in 1976 in Seveso, 
Italy. 
Study design: Nested case-control 
Recruitment of participants:  Data from the 
Seveso Women’s Health Study (SWHS), a 
historical cohort study of the female 
population residing around Seveso at the 
time of the explosion in 1976, was used. 
The 981 women were infants to 40 years 
old in 1976, had resided in one of the most 
highly contaminated zones, A or B, and had 
adequate stored sera collected soon after 
the explosion. 
Method: An interview was conducted by a 
trained nurse-interviewer who was blinded 
to serum TCDD levels and zone of 
residence. Blood serum samples stored 
since 1976 were measured by high 
resolution mass spectrometry. For women 
with serum samples collected after 1977, 
the serum TCDD level was back 
extrapolated using a first-order kinetic 
model, assuming a 9-year half-life. 




More than a 2-fold increase in the hazard rate 




The median decreases in summed serum POP 
concentrations (lipid-adjusted) in 1986, 1994, 
2001, and 2007 relative to 1979 were –22%, –
52%, –54%, and –68%, respectively. Substantial 
declines in all POP groups with the exception of 
chlordanes were observed. Time period 
(reflected by sampling year) was the strongest 
descriptor of changes in PCB-153 concentrations. 
Predicted PCB-153 concentrations were 
Check list: 
1. The exposed and non-exposed were comparable in relation to important 
background factors. 
2. The exposed individuals were representative for women being infants to 
40 years old in 1976. 
3. The non-exposed group was selected from the same population as the 
exposed group. 
4. The study was mostly not prospective, except some back extrapolations. 
5. Exposure and outcome was measured in the same way in the two 
groups. 
6. 981 women were followed, 15 with breast cancer, a little too few cases. 
7. A dropout analysis is done. 
8. The follow-up period could be longer. 
9. Confounders have been made account for. 
10. The interviewer was blinded to serum TCDD levels and zone of 
residence. Medical records were obtained and reviewed by a cancer 
pathologist who was blinded to the woman’s exposure.  
Strengths: The relationship between serum TCDD concentration and breast 
cancer incidence was examined, thus eliminating potential bias associated 
with disease survival. In addition, they collected information in an 
interview, allowing consideration of potential confounding by known risk 
factors in the analysis. Finally, they measured individual serum TCDD 
Conclusion 
Individual serum TCDD is 
significantly related 
Individual serum TCDD is 
significantly related with 
breast cancer incidence 









1976-1981 (a few in 1996-
97) 
consistent with measured concentrations in the 
study population. 
concentrations near the time of exposure, thus minimizing exposure 
misclassification. 
Weaknesses:  small number of breast cancer cases.  
No other studies on the same study groups show correlations between 






Reference: Medehouenou, T. C., et al. (2010). "Determinants of AhR-mediated transcriptional activity induced by plasma 





Aim Material and methods Results Discussion/comments 
Obtain a global measure of 
persistent organic 
pollutants(POPs) in Inuit 
people by assessing AhR-
mediated transcriptional 
activities in blood serum 
samples.  
Study design: Cross-sectional study 
Reruitment of participants: 
permanent Inuit residents of Nunavik 
aged 18 years and older. A stratified 
random sampling of private Inuit 
households with the community 
being the stratification variable was 
used to obtain a standard 
representation of the target 
population. In total, 874 Inuits were 
included.  
Method: Several self-administered 
and interviewer-completed 
questionnaires were used to obtain 
information regarding demographics, 
lifestyle habits, nutrition and health 
indicators. Blood samples and 
anthropometric measures were 
taken. The blood serum was assessed 
using DR-CALUX and GC/MS. SAS 
Software was used to perform all the 
statistical analyses.  
 
 
The geometric mean AhR-mediated activity expressed 
as TEQ was 8,9 pg/g lipids (range <5-144 pg/g lipids). 
PCB-153 concentrations measured by high-resolution 
GC/MS was moderately correlated to AhR-mediated 
activity (Pearson’s R=0,53, p<0,001). Multiple linear 
regression analyses revealed that age and omega-3 
fatty acids in erythrocyte membranes(an index of 
marine food consumption) were positively associated 
with plasma-AhR-mediated activity (p<0,001), whereas 












in Inuit adults 
from Nunavik. 
Check list cross sectional study: 
1. Was the population well defined? Yes 
2. Was the study group representative for the population? Yes 
3. Is it explained if and how the responders differ from the non-
responders? No 
4. Is the answering percentage high enough? 50 %, a little low. 
5. Was the data collection standardized? Yes. 
6. Are objective criterias used for evaluating 
outcomes/exposure? Yes. 
7. Has adequate methods been used in the data analysis? Yes, 
both bioassay and GC/MS is used. 
Strengths: obtained both AhR-mediated activity and concentrations of 
specific POPs in blood serum as well as questionnaires. Inclusion of a 
plasma standard allowed documenting the precision and accuracy of 
the bioassay. Large study group. 
Weaknesses: only 50 % answered.  
What did the writers discuss? The advantage of AhR, the difference in 
results in other studies 
Other literature supporting their findings? Yes. 
Conclusion 
AhR activity increases with 
incremental exposure to 
contaminant from the marine 
food chain in the Inuits. 
Land 
Canada 







Reference:    Recio-Vega R, Velazco-Rodriguez V, Ocampo-Gomez G, Hernandez-Gonzalez S, Ruiz-Flores P, Lopez-Marquez F. Serum 





Aim Material and methods Results Discussion/comments 
Evaluate the relation 
between polychlorinated 
biphenyls (PCB) exposure 
and breast cancer risk in 
Mexican women 
 Study design: case-control 
Participants: 140 women aged 25-80 
years residing in Comarca Lagunera, 
Mexico. 70 of which were newly 
diagnosed with breast cancer, 
identified by biopsi. The 70 controls 
were women with biopsies negative for 
malignancies. 
Method: blood was sampled and 
measured for 20 PCB congeners, both 
non-DL and DLC-PCBs, using GC-
electron capture detection. 
Information regarding 
sociodemographic variables and status, 
reproductive history,lifestyle factors, 
family history of cancer, occupational 
history and diet. Potential sources of 
PCB located close to the 
womenshomes were registered. The 
PCBs were divided in 5 groups 
according to structure-related activity. 
For the total population, 
PCBs in groups 
2b(congeners 128, 138, 
170), 3(153, 180) and 
4(8, 195, 206, 209) and 
total PCBs were 
significantly associated 
with breast cancer. For 
premenopausal women, 
only group 4 was 
significant. For 
postmenopausal 
women, PCB groups 
1a(44,52), 2b and 4 and 
total PCBs were 
significantly associated 
with breast cancer.  
Check list case-control study 
1. Were the cases and controls selected from and comparable to the same population? 
Yes. 
2. Are the groups comparable in relation to important confounders? Yes 
3. Is the disease of the cases sufficiently explained? Yes, identified by biopsies. 
4. Is it clear that the controls did not have the disease? Yes. 
5. Did the authors consider important confounders in the study design and/or analysis? 
Yes 
6. Is the exposure measured and graded in the same way in cases and controls? Yes. 
7. Was the one measuring the exposition blinded for who were cases and controls? No. 
8. Was the response rate high enough in both groups? Not stated. 
Strengths: They have taken into account all important risk factors. Confirmed the diagnosis by 
biopsies. Measuring PCBs using GC/ECD. 
Weaknesses: small groups. 
What did the writers discuss?  Appropriate times for measuring the exposure, their findings 
compared with other studies, the change in exposure of the individuals, the role PCBs play in 
cancer development, and the toxicity of the OCB congeners related to chlorination, and their 
findings of relation of known risk factors and breast cancer. 
Other literature supporting their findings? Our data are consistent with some but not all 
published studies in which the general population with relatively low levels of environmental 
exposure has been assessed. They assess these inconsistencis to origin from differences in the 
groups  in the different studies. 
Conclusion 
They showed an 
association between heavy 
and potentially estrogenic 




Year of sampling data 
Not given 
